Viral Engineering

Modified Vesicular Stomatitis Virus Suitable For Cancer Therapy

Published in Cancer Weekly, January 29th, 2002

by Sonia Nichols, senior medical writer - Genetically modified vesicular stomatitis virus (VSV) may be useful in recombinant therapies directed towards treating cancer, researchers at the University of Miami School of Medicine report.

In fact, the researchers, led by M. Fernandez, have developed several recombinant therapies incorporating the genetically engineered vectors and determined they are useful for battling tumors and increasing survival in murine models of several forms of malignancies.

Vectors developed by Fernandez and coworkers express thymidine kinase (TK), a suicide gene product, or interleukin (IL-4), a cytokine, according to the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry